KR102343947B1 - A business model using system for monitoring of recurrent and metastatic cancer using patient information analysis - Google Patents

Abstract

A business model using the cancer recurrence and metastasis monitoring system using patient information analysis of the present invention includes: a regional hospital diagnosis system that collects blood from patients treated for cancer and collects clinical information of patients; a delivery system that delivers the collected blood; and a cancer metastasis/recurrence analysis system that comprehensively analyzes the blood and the patient's clinical information to analyze the possibility of cancer metastasis and recurrence, and transmits an analysis report to the local hospital diagnosis system.

Description

{A business model using system for monitoring of recurrent and metastatic cancer using patient information analysis}

The present invention relates to a business model using a cancer recurrence and metastasis monitoring system. More specifically, it is possible to diagnose whether cancer has recurred and whether cancer has metastasized during the observation period of a cancer patient who has finished chemotherapy at a nearby hospital. It is about a business model using a system that performs a method.

The cancer that first occurred in the patient is called “primary cancer”, and when cancer recurs in the same site within a certain period of time, it is “recurrent cancer”, and after a certain period of time, cancer reoccurs in the same site, or another cancer occurs regardless of the period. When cancer develops in the site, it is called “metastatic cancer (=secondary cancer)”. According to the National Cancer Information Center, the risk of primary cancer recurrence is high in patients who have had cancer at least once, but the incidence of secondary cancer is also on average 2.3 times higher than that of normal people of the same age.

In general, most patients undergoing surgery in a large hospital and receiving chemotherapy visit outpatient clinics every 6 months to check for cancer progression. However, such treatment services provided by large hospitals do not provide sufficient explanation to patients, and there is a problem in monitoring recurrent or metastatic cancer through such insufficient treatment.

In addition, it is not an exaggeration to say that since the treatment environment was centered on tertiary hospitals such as university hospitals, there was little role played by local hospitals. However, the number of regional hospitals is higher than that of tertiary hospitals, and cancer patients can easily access them, so it is necessary to increase the role of regional hospitals. This is because we can build a healthier health care system.

In such an environment, tertiary hospitals such as university hospitals are in charge of treatment, and primary and secondary hospitals such as regional hospitals with high patient access need to be dedicated to screening for recurrent and metastatic cancer.

delete

Patent Document 1: Korean Patent Publication No. 10-2018-0051990 (published on May 17, 2018)

The present invention provides a business model using a cancer recurrence and metastasis monitoring system using patient information analysis that can monitor a patient's recurrent cancer and metastasis by analyzing the patient's blood information and clinical information centering on a local hospital with high patient access. intended to provide

According to an embodiment of the present invention, a business model using a cancer recurrence and metastasis monitoring system using patient information analysis includes: a local hospital diagnosis system that collects blood from a patient treated for cancer and collects clinical information of the patient; a delivery system that delivers the collected blood; and a cancer metastasis/recurrence analysis system that comprehensively analyzes the blood and the patient's clinical information to analyze the possibility of cancer metastasis and recurrence, and transmits an analysis report to the local hospital diagnosis system.

Here, the cancer metastasis/relapse analysis system performs deep learning analysis on the information of cell-free DNA contained in the blood, information on CTC of blood cancer cells isolated from the blood, and the clinical information to detect cancer metastasis and It may include; a deep learning comprehensive analysis unit that writes an analysis report on the possibility of recurrence.

In addition, the cancer metastasis / recurrence analysis system analyzes the genome of the tumor tissue cultured by animal testing the blood cancer cells extracted from the blood to provide information on anticancer drug sensitivity and secondary anticancer drug selection, resulting in additional test costs. It may further include an additional precision analysis module;

In addition, the regional hospital diagnosis system includes: a patient information collection system that collects the blood, collects the clinical information, and transmits it to the cancer metastasis/relapse analysis system; It may include; a treatment system that manages the treatment history.

In addition, the patient information collection system, a CT image or MRI image of the affected part, the patient's blood pressure and blood sugar, and a clinical information collection unit for collecting information on the patient's lifestyle or symptoms; and a blood collection unit that collects blood from the patient and stores it in a refrigerator, and collects and stores the patient's blood pressure, body temperature, and environmental information during blood collection.

In addition, the medical treatment system may automatically receive to the patient an analysis cost of the cancer metastasis/recurrence analysis system and an examination fee including a delivery cost of the blood and clinical information.

In addition, the medical treatment system may store face-to-face consultation history information between the patient and the doctor using the analysis report transmitted from the cancer metastasis/relapse analysis system, and receive instructions for re-examination or detailed examination according to the doctor's opinion. have.

In addition, the delivery system provides an emergency delivery service for refrigerated storage of the blood and delivery to the cancer metastasis/recurrence analysis system, and a document of the analysis report and the written clinical information to the cancer metastasis/relapse analysis system and the regional hospital diagnosis It may include general shipping services that ship between systems.

In addition, the delivery system may charge the local hospital diagnosis system by differentially applying the delivery costs of the emergency delivery service and the general delivery service.

According to the business model using the cancer recurrence and metastasis monitoring system using the patient information analysis of the present invention, it is easy to monitor recurrent and metastatic cancer even in a local hospital where patients can easily access and receive treatment and consultation, and You can receive differentiated treatment.

1 is a schematic diagram illustrating a cancer recurrence and metastasis monitoring system using the present patient information analysis.
2 is a schematic diagram showing cancer recurrence and metastasis treatment carried out in the regional hospital of FIG. 1 .
3 is a schematic diagram illustrating shipping a blood sample collected in a patient information collection system.
4 is a schematic diagram showing an analysis platform for cancer metastasis and recurrence of a cancer metastasis/relapse analysis institution.
5 is a flowchart illustrating a method for monitoring cancer recurrence and metastasis using patient information analysis.

Hereinafter, with reference to the accompanying drawings, the embodiments of the present invention will be described in detail so that those of ordinary skill in the art to which the present invention pertains can easily implement them. The present invention may be embodied in many different forms and is not limited to the embodiments described herein. In order to clearly explain the present invention in the drawings, parts irrelevant to the description are omitted, and the same reference numerals are assigned to the same or similar components throughout the specification.

In the present specification, terms such as “comprise” or “have” are intended to designate that a feature, number, step, operation, component, part, or combination thereof described in the specification exists, but one or more other features It should be understood that it does not preclude the possibility of the presence or addition of numbers, steps, operations, components, parts, or combinations thereof. Also, when a part of a layer, film, region, plate, etc. is said to be “on” another part, this includes not only the case where the other part is “directly on” but also the case where there is another part in between. Conversely, when a part of a layer, film, region, plate, etc. is said to be "under" another part, this includes not only cases where it is "directly under" another part, but also cases where there is another part in between.

1 is a schematic diagram showing a cancer recurrence and metastasis monitoring system 100 using the present patient information analysis, FIG. 2 is a schematic diagram showing cancer recurrence and metastasis treatment carried out in the regional hospital of FIG. 1 , and FIG. 3 is patient information It is a schematic diagram showing delivery of a blood sample collected in a collection system, FIG. 4 is a schematic diagram showing an analysis platform for cancer metastasis and recurrence of a cancer metastasis/relapse analysis institution, and FIG. 5 is cancer recurrence and metastasis using patient information analysis It is a flowchart showing the monitoring method.

1 to 4, the cancer recurrence and metastasis monitoring system 100 using patient information analysis according to an embodiment of the present invention includes a regional hospital diagnosis system 110, a delivery system 120, and a cancer metastasis/ a relapse analysis system 130 .

The local hospital diagnosis system 110 is provided in a primary or secondary hospital that is easy for cancer patients to access so that periodic follow-up of cancer patients is possible, and includes a patient information collection system 111 that collects patient's pathological information and It may include a medical treatment system 114 that manages the patient's revisit schedule, the patient's medical history, manages the re-examination and re-analysis schedule, and receives treatment and examination fees. In addition, in the treatment system 114, medical staff (doctors, nurses) who face-to-face with the patient and perform consulting on the patient's cancer recurrence and metastasis possibility, the need for additional detailed analysis, selection of a re-analysis period, selection of secondary anticancer drugs, and lifestyle may be included.

Referring to FIG. 2 , the patient information collection system 111 of the regional hospital diagnosis system 110 includes a clinical information collection unit 112 that collects clinical information of a patient and a blood collection unit 113 that manages blood collected from the patient. It may be composed of

The clinical information collection unit 112 collects various pathological histories of the patient. For example, information such as computed tomography (CT) or magnetic resonance imaging (Magnetic Resonance Imaging) of the patient's affected area, information such as the patient's blood pressure or blood sugar, and patient lifestyle and various symptoms collected through questionnaires or tablet PCs can be collected. can The clinical information collected in this way is then transmitted to the cancer metastasis/relapse analysis system 130 to be used as analysis data. Various information collected through the clinical information collection unit 112 is transmitted to the cancer metastasis/recurrence analysis system 130 through e-mail or the like, and may be transmitted through the delivery system 120 if necessary.

The blood collection unit 113 is for collecting blood from a patient and managing it, and includes a refrigerator to prevent deterioration of blood, and comprehensively collects blood glucose and blood pressure information of the patient during blood collection. stored and managed as Additionally, additional information such as a patient's body temperature, pulse, and electrocardiogram can be collected and managed during blood collection. The blood collected by the blood collection unit 113 may be stored in a refrigerator or the like to prevent deterioration, and then transferred to the cancer metastasis/recurrence analysis system 130 through the delivery system 120 .

The medical treatment system 114 of the local hospital diagnosis system 110 comprehensively manages the patient's revisit schedule, the patient's medical history, the re-examination and re-analysis schedule management, and the receipt of treatment and examination costs, and at the same time, face-to-face treatment between the doctor and the patient It is possible to store and store the history and consultation details of the patient's additional examination, re-examination, and detailed examination. The medical treatment system 114 can be largely divided into a schedule management unit 115 and a diagnosis and treatment 116 , and the diagnosis and treatment 116 provides a metastasis/recurrence analysis report ( 133), mainly face-to-face consultations between doctors and patients, and various information such as voice consultation files, written consultation files, patient re-examination, additional examinations, detailed examinations, and anticancer drug selection can be managed comprehensively. In the diagnosis and treatment 116, the doctor explains to the patient about the possibility of cancer metastasis/recurrence analyzed through the metastasis/relapse analysis report 133, and if necessary, a diagnosis for detailed analysis and a diagnosis for secondary anticancer drugs. have. If there are good signs of cancer metastasis and recurrence, a schedule for reexamination and reanalysis may be established. In addition, the patient's lifestyle consulting may be performed in detail based on the patient's lifestyle and biometric information collected through the clinical information collection unit 112 . In addition, the medical treatment system 114 may receive medical expenses and examination fees from the patient. Analysis of cancer metastasis and recurrence is not covered by health insurance until now, and claims for examination fees may be automatically managed and claimed by the medical treatment system 114 . The examination fee may include the cost for cancer metastasis and recurrence analysis, as well as the cost for blood and report delivery. It can be managed on a post-paid basis.

Referring to FIG. 3 , the delivery system 120 is for delivering blood and a report between the regional hospital diagnosis system 110 and the cancer metastasis/recurrence analysis system 130 , and includes an emergency delivery service 121 and a general delivery service. (122). For both services, a different delivery fee may be charged depending on the delivery date and delivery status.

The emergency delivery service 121 may be mainly applied to deliver a blood sample to the cancer metastasis/recurrence analysis system 130 , and a dedicated delivery vehicle equipped with a refrigeration device may be applied to prevent blood deterioration. The general delivery service 122 mainly delivers the written analysis report produced from the cancer metastasis/recurrence analysis system 130 to the regional hospital diagnosis system 110, or the patient's clinical information ( blood) to the cancer metastasis/relapse analysis system 130 .

The cancer metastasis/recurrence analysis system 130 comprehensively and precisely analyzes the patient's blood sample and the patient's clinical information delivered from the local hospital diagnosis system 110 to produce a cancer metastasis/relapse analysis report, which is then used in the local hospital diagnosis system (110) for transmission. Referring to FIG. 4 , the cancer metastasis/relapse analysis system 130 may include a deep learning comprehensive analysis 131 . The deep learning comprehensive analysis 131 separates the information of the blood cancer cell genome analysis unit (Cell-free DNA) that analyzes the CfDNA blood cancer cell genome contained in the patient's blood and the blood cancer cell (CTC) in the blood, and the separated CTC genome By using deep learning techniques to comprehensively analyze the information of the Circulating Tumor Cell (CTC) in the blood and clinical information such as CT/MRI, blood pressure, and blood sugar of the patient, A detailed inspection can be carried out.

More specifically, cell-free DNA present in blood can be observed when cancer cells in the site of primary cancer are damaged by physical action, or when DNA of cells moves into the blood. Alternatively, Cell-Free DNA can be observed even when cancer cells are destroyed by physical action while moving through the blood. In general, it can be observed that the amount of cfDNA (=Cell-Free DNA) increases in terminal cancer patients. Therefore, when cfDNA present in the blood of cancer patients is analyzed based on this association, genomic mutations found in tumors can be found. In other words, blood samples from cancer patients can be analyzed to monitor recurrence and metastasis. In addition, cancer recurrence and metastasis can be predicted by isolating blood cancer cell CTC (Circulating Tumor Cell) from a blood sample, culturing the isolated blood cancer cell CTC, and applying a Patient Driven Xenograft (PDX) model. In addition, the deep learning comprehensive analysis 131 applies supervised learning of machine learning to the clinical information of the patient, calculates the recurrence and metastasis of cancer, and applies machine learning to the extracted mutation information data and clinical information. It is possible to generate a report on the recurrence and metastasis of cancer by calculating the risk through the variability information and database for each disease.

In addition, the cancer metastasis/relapse analysis system 130 may further include an additional precision analysis module 132 that provides additional information. The additional precision analysis module 132 provides information on anticancer drug sensitivity and secondary anticancer drug selection by culturing tumor tissue by conducting animal experiments based on blood cancer cells extracted from patient blood, and analyzing the genome of the tumor tissue can do. The additional detailed analysis module 132 may be performed when necessary according to a diagnosis of a doctor or a request of a patient, and an examination cost may be calculated in addition to the basic cancer metastasis/recurrence analysis cost.

The cancer metastasis/recurrence analysis report 133 produced by the cancer metastasis/recurrence analysis system 130 is primarily transmitted to the local hospital diagnosis system 110 online through e-mail, etc., and additionally through the delivery system 120 A written report of the metastasis/relapse analysis report 133 may be delivered. Delivery of written reports may be optional.

As described above, the method for monitoring cancer recurrence and metastasis in a patient using the cancer recurrence and metastasis monitoring system using patient information analysis according to an embodiment of the present invention is described in FIG. 5 , in the blood and clinical information collection step (S100) , examination fee receipt step (S200), blood and clinical information delivery step (S300), metastasis/recurrence analysis and report writing step (S400), report transmission and billing step (S500), and cancer tracking treatment step (S600) can

The blood and clinical information collection step (S100) is performed in the local hospital diagnosis system 110, and the patient's CT/MRI, blood pressure, blood sugar, and lifestyle are collected from the clinical information collection unit 112 of the patient information collection system 111. Conduct observable surveys to collect patient information. In addition, the blood collection unit 113 of the patient information collection system 111 collects and stores the patient's blood, and various biometric information and surrounding environment information of the patient may also be collected and managed during blood collection.

In the examination fee receiving step ( S200 ), in addition to the examination fee required for deep learning analysis in the cancer metastasis/recurrence analysis system 130 , the delivery fee required for delivery of blood and written report may be included. Blood is delivered in a dedicated vehicle equipped with a refrigeration system to prevent deterioration, and written reports are delivered in a regular vehicle, so different delivery costs may apply.

The blood and clinical information delivery step (S300) is to transmit the blood and clinical information collected from the local hospital diagnosis system 110 to the cancer metastasis / recurrence analysis system 130, and the blood or written clinical information is delivered to the delivery system 120 The digital clinical information of the patient can be delivered through online transmission means such as e-mail.

In the metastasis/recurrence analysis and report writing step (S400), the patient's blood and clinical information delivered from the local hospital diagnosis system 110 are comprehensively analyzed by deep learning to derive a comprehensive diagnosis result on the possibility of cancer metastasis or recurrence of the patient. And based on this, you can create an analysis report. In principle, the cancer metastasis/recurrence analysis report is transmitted online to the local hospital diagnosis system 110 within 2 days after the blood delivery is completed. .

In the report transmission and billing step (S500), the analysis report completed after analysis by the cancer metastasis/recurrence analysis system 130 is transmitted to the local hospital diagnosis system 110, and is primarily transmitted through means such as e-mail In addition, the written analysis report may be delivered using the delivery system 120 . In this case, the cancer metastasis/recurrence analysis system 130 may charge the examination fee required for the analysis to the local hospital diagnosis system 110 , and if additional service is performed, it may charge in addition to the examination fee. If the cancer metastasis/recurrence analysis system 130 charges for the cost, the regional hospital diagnosis system 110 may directly transfer the stored examination fee to the cancer metastasis/relapse analysis system 130 to make payment.

The cancer follow-up treatment step (S600) is performed by face-to-face treatment between the doctor and the patient based on the metastasis/relapse analysis report written in the cancer metastasis/relapse analysis system 130 and the clinical information of the patient. All can be digitized and archived. When the possibility of cancer recurrence or metastasis is high during consultation with a doctor, or if a detailed examination is required, the doctor will derive the diagnosis result for additional or re-examination, and in this case, additional examination may be performed. That is, cancer patients can receive precise diagnosis results for the possibility of cancer metastasis or recurrence within up to 2 to 3 days after blood collection, making it very easy and quick to follow up on treatment cancer.

In addition to this, in the cancer follow-up treatment step (S600), according to the doctor's opinion based on the cancer metastasis/recurrence analysis report, a re-examination or a detailed examination may be performed, and accordingly, the re-examination fee receipt step (S700), re/precision examination It may further include a request step (S800), a re/precision analysis and report writing step (S900), a re/precision analysis report transmission and billing step (S1000), and a re/precision treatment step (S1100).

The re-examination fee receiving step (S700) is a step of receiving a re-examination fee generated according to the doctor's re-examination or detailed examination opinion. If it is necessary to perform an analysis module (animal experimentation and analysis of secondary anticancer drugs), an additional detailed analysis fee may be additionally charged in addition to the basic examination fee.

The re/examination request step (S800) is to transmit patient information from the regional hospital diagnosis system 110 to the cancer metastasis/relapse analysis system 130. According to the doctor's opinion, the patient's blood is drawn again and CT/MRI is performed. Other clinical information including, but not limited to, can be collected and transmitted again. In patients with high cancer metastasis, metastasis can proceed very rapidly depending on the location of the lesion, so blood collection and clinical information re-collection can be performed according to the doctor's professional opinion.

In the re/precise analysis and report writing step (S900), the patient's blood and clinical information delivered from the local hospital diagnosis system 110 are comprehensively analyzed by deep learning to derive comprehensive diagnostic results on the possibility of cancer metastasis or recurrence of the patient. And based on this, you can create an analysis report. At this time, when the additional precision analysis module is selected according to the opinion of the doctor, an animal experiment is performed based on the blood cancer cells to culture the tumor tissue, and the genome of the cultured tumor tissue may be analyzed and the result may be provided. In addition, an analysis of anticancer drug susceptibility is performed, and analysis results that are referenced for secondary anticancer drug selection based on animal test results can be provided as a report.

The re/precise analysis report transmission and billing step (S1000) is to transmit the analysis report completed after analysis by the cancer metastasis/recurrence analysis system 130 to the regional hospital diagnosis system 110, primarily by e-mail, etc. means, and the written analysis report may be delivered utilizing the delivery system 120 . In this case, the cancer metastasis/recurrence analysis system 130 may charge the examination fee required for the analysis to the local hospital diagnosis system 110 , and if additional service is performed, it may charge in addition to the examination fee. If the cancer metastasis/recurrence analysis system 130 charges for the cost, the regional hospital diagnosis system 110 may directly transfer the stored examination fee to the cancer metastasis/relapse analysis system 130 to make payment.

The re/precision treatment step ( S1100 ) is performed by face-to-face treatment between a doctor and a patient based on the metastasis/recurrence analysis report prepared by the cancer metastasis/relapse analysis system 130 and clinical information of the patient. In particular, in the re/precision treatment step (S1100), precise follow-up of the patient's viability is performed, and if necessary, the patient may be transferred to a tertiary large hospital. Through such continuous follow-up care, periodic precise monitoring of the patient can be carried out, thereby relieving the patient's psychological anxiety and improving the patient's chances of survival by predicting recurrence.

Although the embodiments of the present invention have been described above, the spirit of the present invention is not limited to the embodiments presented herein, and those skilled in the art who understand the spirit of the present invention can add components, Other embodiments may be easily proposed by changes, deletions, additions, etc., but these will also fall within the scope of the present invention.

100: Cancer recurrence and metastasis monitoring system
110: local hospital diagnostic system
120: delivery system
130: cancer metastasis / recurrence analysis system

Claims (6)

a regional hospital diagnosis system that collects blood from cancer patients and collects clinical information from patients;
a delivery system that delivers the collected blood; and
and a cancer metastasis/recurrence analysis system that comprehensively analyzes the blood and the patient's clinical information to analyze the possibility of cancer metastasis and recurrence, and transmits an analysis report to the local hospital diagnosis system,
The local hospital diagnosis system,
a patient information collection system that collects the blood, collects the clinical information, and transmits it to the cancer metastasis/relapse analysis system; and
and a treatment system that receives treatment and examination costs from the patient and manages the patient's examination schedule and treatment history,
The patient information collection system,
a clinical information collection unit that collects CT or MRI images of the affected area, blood pressure and blood sugar of the patient, and information on the patient's lifestyle or symptoms; and
and a blood collection unit that collects blood from the patient and refrigerates it, and collects and stores the patient's blood pressure, body temperature, and environmental information during blood collection;
The treatment system is
analysis cost of the cancer metastasis/relapse analysis system; and
The blood, the cost of a dedicated vehicle equipped with a refrigeration system to prevent deterioration of the blood, and the examination cost including the clinical information delivery cost are calculated and automatically stored in the patient,
A method for monitoring cancer recurrence and metastasis using patient information analysis that enables the patient's viability and transfer to a tertiary large hospital through periodic monitoring of the patient.
The method according to claim 1,
The cancer metastasis / recurrence analysis system,
Deep learning that prepares an analysis report on the possibility of cancer metastasis and recurrence of the patient by deep learning analysis of the cell-free DNA information contained in the blood, the blood cancer cell CTC information isolated from the blood, and the clinical information Comprehensive analysis unit; cancer recurrence and metastasis monitoring method using patient information analysis, including.
3. The method according to claim 2,
The cancer metastasis / recurrence analysis system,
An additional precision analysis module in which additional test costs are incurred by analyzing the genome of tumor tissue cultured by animal testing of blood cancer cells extracted from the blood to provide information on anticancer drug sensitivity and secondary anticancer drug selection; Patient information including Methods for monitoring cancer recurrence and metastasis using assays

delete delete delete

Images